Suppr超能文献

人小肠和大肠不同部位腔液中的药物溶解度。

Drug solubility in luminal fluids from different regions of the small and large intestine of humans.

机构信息

Department of Pharmaceutics, The School of Pharmacy, University of London, 29-39 Brunswick Square, London, WC1N 1AX, UK.

出版信息

Mol Pharm. 2010 Oct 4;7(5):1527-32. doi: 10.1021/mp100198q. Epub 2010 Sep 15.

Abstract

The purpose of this work was to study the solubility of two drugs with different physicochemical properties in luminal fluids obtained from various regions of the human gastrointestinal (GI) tract and to determine the most important luminal parameters influencing their solubility. Jejunal fluids were aspirated from healthy volunteers via an oral intubation tube. Ileal and colonic fluids were obtained from patients undergoing GI surgery. Stoma fluids were also retrieved from patients. pH and buffer capacity of all fluids were determined. Saturation solubility of prednisolone (unionisable) and mesalamine (5-aminosalicylic acid) (zwitterionic) was measured. Mean solubility of prednisolone in the different luminal fluids was 0.50 mg/mL (±0.05) and did not vary significantly between the different regions of the GI tract (ANOVA, p > 0.05). No correlation between prednisolone solubility and jejunal bile salt content was found. Mesalamine solubility increased down the GI tract: 1.97 (±0.25), 3.26 (±0.08), 6.24 (±1.13) and 7.95 (±0.21) mg/mL in jejunal, ileal, ascending and transverse/descending colonic fluids respectively. Buffer capacity also increased and in one patient was observed to range from 6.4 to 28.6 reaching 44.4 mM/L/pH unit in ileal, ascending and transverse/descending colon fluids respectively. Mesalamine solubility was found to be dependent on both buffer capacity and pH, with buffer capacity being the most important (standardized coefficient β = 0.849, p < 0.0001) compared to pH (β = 0.219, p < 0.05). For drugs delivered as modified release formulations it is important to consider solubility in different regions of the GI tract as significant differences can arise which will ultimately influence drug bioavailability.

摘要

这项工作的目的是研究两种具有不同理化性质的药物在人胃肠道不同部位获得的腔液中的溶解度,并确定影响其溶解度的最重要的腔液参数。通过口服插管从健康志愿者中抽吸空肠液。从接受胃肠道手术的患者中获得回肠和结肠液。还从患者中获取造口液。测定所有液体的 pH 值和缓冲能力。测量泼尼松龙(可结合)和美沙拉嗪(5-氨基水杨酸)(两性离子)的饱和溶解度。泼尼松龙在不同腔液中的平均溶解度为 0.50mg/mL(±0.05),并且在胃肠道的不同部位之间没有显著差异(ANOVA,p>0.05)。未发现泼尼松龙溶解度与空肠胆盐含量之间存在相关性。美沙拉嗪的溶解度沿着胃肠道增加:在空肠、回肠、升结肠和横结肠/降结肠液中分别为 1.97(±0.25)、3.26(±0.08)、6.24(±1.13)和 7.95(±0.21)mg/mL。缓冲能力也增加,在一名患者中观察到在回肠、升结肠和横结肠/降结肠液中分别从 6.4 到 28.6 变化,达到 44.4mM/L/pH 单位。发现美沙拉嗪的溶解度取决于缓冲能力和 pH 值,缓冲能力是最重要的(标准化系数 β=0.849,p<0.0001),而 pH 值则是次要的(β=0.219,p<0.05)。对于作为控释制剂给药的药物,重要的是要考虑在胃肠道的不同部位的溶解度,因为可能会出现显著差异,这最终会影响药物的生物利用度。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验